Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
CSE: CMND
FWB: CWY
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
22
May
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Dis
Read More
17
May
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
12
May
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
Read More
8
May
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Read More
2
May
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
Read More
27
April
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
Read More
21
April
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
Read More
20
April
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
Read More
6
April
Clearmind Medicine Closes US$3.5 Million Public Offering
Read More
16
March
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Read More
14
March
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D. to Scientific Advisory Board
Read More
22
February
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
Read More
15
February
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
Read More
8
February
Israel-Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More
31
January
Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
Read More
Next
